FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 352:1283-1285 March 31, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

After sitting through three days of testimony and debate last month, a panel of experts advising the Food and Drug Administration (FDA) rendered an ambivalent verdict on the future of the cyclooxygenase-2 (COX-2) inhibitors. On the one hand, the 32 members of the advisory committee agreed that these drugs for pain and arthritis pose serious hazards. They voted unanimously that the available evidence on the three approved "coxibs" — rofecoxib, celecoxib, and valdecoxib — supports the conclusion that each of the drugs significantly increases users' risk of cardiovascular events, including heart attacks and strokes. Nonetheless, the committee also voted, by . . . [Full Text of this Article]

Source Information

Dr. Okie is a contributing editor of the Journal.

This article has been cited by other articles:

• GEE, J. R., BURMEISTER, C. B., HAVIGHURST, T. C., KIM, K. (2009). Cyclin-mediated G1 Arrest by Celecoxib Differs in Low-versus High-grade Bladder Cancer. Anticancer Res 29: 3769-3775 [Abstract] [Full Text]  
• Jia, Z., Guo, X., Zhang, H., Wang, M.-H., Dong, Z., Yang, T. (2008). Microsomal Prostaglandin Synthase-1-Derived Prostaglandin E2 Protects Against Angiotensin II-Induced Hypertension via Inhibition of Oxidative Stress. Hypertension 52: 952-959 [Abstract] [Full Text]  
• Eligini, S., Barbieri, S. S., Arenaz, I., Tremoli, E., Colli, S. (2007). Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets: Role of transforming growth factor-{beta}1. Cardiovasc Res 74: 270-278 [Abstract] [Full Text]  
• Schneider, V., Levesque, L. E., Zhang, B., Hutchinson, T., Brophy, J. M. (2006). Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis. Am J Epidemiol 164: 881-889 [Abstract] [Full Text]  
• Pruthi, R. S., Derksen, J. E., Moore, D., Carson, C. C., Grigson, G., Watkins, C., Wallen, E. (2006). Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy.. Clin. Cancer Res. 12: 2172-2177 [Abstract] [Full Text]  
• Caporali, R, Montecucco, C (2005). Cardiovascular effects of coxibs. Lupus 14: 785-788 [Abstract]  
• Jones, S C. (2005). Relative Thromboembolic Risks Associated with COX-2 Inhibitors. The Annals of Pharmacotherapy 39: 1249-1259 [Abstract] [Full Text]